A phase II evaluation of pemetrexed (LY231514, IND #40061) in the treatment of recurrent or persistent platinum-resistant ovarian or primary peritoneal carcinoma: A study of the gynecologic oncology group

被引：4
|
作者：
Miller, D. S.
Blessing, J. A.
Krasner, C. N.
Mannel, R. J.
机构：
[1] Univ Texas SW Med Ctr Dallas, Dallas, TX 75390 USA
[2] Roswell Pk Canc Inst, Buffalo, NY 14263 USA
[3] Massachusetts Gen Hosp, Boston, MA 02114 USA
[4] Univ Oklahoma, Oklahoma City, OK USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2008年 / 26卷 / 15期
关键词：
D O I：
10.1200/jco.2008.26.15_suppl.5524
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5524
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Evaluation of pemetrexed (Alimta, LY231514) as second-line chemotherapy in persistent or recurrent carcinoma of the cervix: the CERVIX 1 study of the MITO (Multicentre Italian Trials in Ovarian Cancer and Gynecologic Malignancies) Group
    Lorusso, D.
    Ferrandina, G.
    Pignata, S.
    Ludovisi, M.
    Vigano, R.
    Scalone, S.
    Scollo, P.
    Breda, E.
    Pietragalla, A.
    Scambia, G.
    ANNALS OF ONCOLOGY, 2010, 21 (01) : 61 - 66
  • [22] Phase II Clinical Trial of Ixabepilone in Patients With Recurrent or Persistent Platinum- and Taxane-Resistant Ovarian or Primary Peritoneal Cancer: A Gynecologic Oncology Group Study
    De Geest, Koen
    Blessing, John A.
    Morris, Robert T.
    Yamada, S. Diane
    Monk, Bradley J.
    Zweizig, Susan L.
    Matei, Daniela
    Muller, Carolyn Y.
    Richards, William E.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (01) : 149 - 153
  • [23] A phase II evaluation of tirapazamine plus cisplatin in the treatment of recurrent platinum-sensitive ovarian or primary peritoneal cancer: A Gynecologic Oncology Group study
    Covens, A
    Blessing, J
    Bender, D
    Mannel, R
    Morgan, M
    GYNECOLOGIC ONCOLOGY, 2006, 100 (03) : 586 - 590
  • [24] A phase II evaluation of motesanib (AMG 706) in the treatment of persistent or recurrent ovarian, fallopian tube and primary peritoneal carcinomas: A Gynecologic Oncology Group study
    Schilder, R. J.
    Sill, M. W.
    Lankes, H. A.
    Gold, M. A.
    Mannel, R. S.
    Modesitt, S. C.
    Hanjani, P.
    Bonebrake, A. J.
    Sood, A. K.
    Godwin, A. K.
    Hu, W.
    Alpaugh, R. K.
    GYNECOLOGIC ONCOLOGY, 2013, 129 (01) : 86 - 91
  • [25] Phase II study of gemcitabine and vinorebline in patients with persistent or recurrent platinum-resistant ovarian or primary peritoneal cancer: A study of the Korean Cancer Study Group.
    Hong, Sook Hee
    Byun, Jae Ho
    Lee, Soohyeon
    Kim, Hoon-Gu
    Lee, Hyo Jin
    Jung, Kyung Hae
    Lee, Sang-Cheol
    Lee, Na-Ri
    Yun, Jina
    Hong, Dae-Sik
    Woo, In Sook
    Park, Kyong Hwa
    Rha, Sun Young
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [26] A phase II evaluation of brivanib in the treatment of persistent or recurrent carcinoma of the cervix: An NRG Oncology/Gynecologic Oncology Group study
    Chan, John K.
    Deng, Wei
    Higgins, Robert V.
    Tewari, Krishnansu S.
    Bonebrake, Albert J.
    Hicks, Michael
    Gaillard, Stephanie
    Ramirez, Pedro T.
    Chafe, Weldon
    Monk, Bradley J.
    Aghajanian, Carol
    GYNECOLOGIC ONCOLOGY, 2017, 146 (03) : 554 - 559
  • [27] Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: A Gynecologic oncology group study
    Burger, Robert A.
    Sill, Michael W.
    Monk, Bradley J.
    Greer, Benjamin E.
    Sorosky, Joel I.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (33) : 5165 - 5171
  • [28] A phase II trial of paclitaxel poliglumex in recurrent or persistent ovarian or primary peritoneal cancer (EOC): A gynecologic oncology group study
    Sabbatini, Paul
    Sill, Michael W.
    O'Malley, David
    Adler, Lisa
    Secord, Angeles Alvarez
    GYNECOLOGIC ONCOLOGY, 2008, 111 (03) : 455 - 460
  • [29] Assessment of tumor response as a surrogate endpoint of survival in recurrent/platinum-resistant ovarian carcinoma: A Gynecologic Oncology Group study
    Rose, Peter G.
    Tian, Chunqiao
    Bookman, Michael A.
    GYNECOLOGIC ONCOLOGY, 2010, 117 (02) : 324 - 329
  • [30] A phase II study of bevacizumab with nab-paclitaxel in patients with recurrent, platinum-resistant primary epithelial ovarian or primary peritoneal carcinoma
    Tillmanns, T. D.
    Lowe, M. P.
    Schwartzberg, L. S.
    Walker, M. S.
    Stepanski, E. J.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
12345